Business context and reporting period
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders. This Form 10-K reports the fiscal year ended December 31, 2022; it is an annual report, and the filing does not provide a separate fourth-quarter income statement or cash flow statement.
Key programs include VK2809, in a Phase 2b trial for NASH; VK0214, in a Phase 1b trial for X-linked adrenoleukodystrophy; and VK2735, a dual GLP-1/GIP agonist in Phase 1. The company has no approved products or product revenue.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $54.2 million | $45.0 million |
| General and administrative expense | $16.1 million | $10.7 million |
| Operating loss | $70.4 million | $55.7 million |
| Net loss | $68.9 million | $55.0 million |
| Basic and diluted loss per share | $0.90 | $0.71 |
| Net cash used in operating activities | $48.4 million | $47.6 million |
At December 31, 2022, cash and cash equivalents were $36.6 million and short-term investments were $118.9 million, totaling $155.5 million. Total assets were $168.5 million, total liabilities $23.2 million, and stockholders’ equity $145.3 million. The filing reports no borrowings; liabilities included accounts payable, accrued liabilities, and operating lease obligations. Profit margins are not meaningful given the absence of revenue.
Investing activities provided $54.8 million, primarily reflecting investment maturities net of purchases, not operating cash generation. Financing activities provided $4.2 million, including $11.7 million of net ATM proceeds, offset in part by $6.8 million of share repurchases. The company repurchased 729,034 shares under its new repurchase program during 2022.
Changes versus the prior year
- Net loss increased $13.9 million, or approximately 25%, from 2021; operating loss increased $14.7 million.
- R&D expense rose 20.6%, mainly due to drug manufacturing, preclinical work, salaries, benefits, and stock-based compensation; clinical study and consultant costs partly offset the increase.
- G&A expense rose 50.6%, primarily reflecting legal costs, stock-based compensation, salaries, benefits, and insurance.
- Operating cash use was broadly similar to 2021, increasing by $0.8 million.
- Year-end cash and short-term investments fell from $202.1 million in 2021 to $155.5 million in 2022, while the company also repurchased shares and raised capital through its ATM program.
Outlook, risks, contingencies, and notable items
- Management expected existing cash, cash equivalents, and investments to fund operations through at least the first quarter of 2024, based on its operating plan. It also expects continued losses, potentially increasing as development advances, and says additional capital will be needed to fund operations and trials.
- In January 2023, after year-end, Viking reported completion of enrollment in the VK2809 VOYAGE Phase 2b study and expected primary-endpoint data in the first half of 2023. This was management’s stated expectation, not a reported result.
- VK5211’s Phase 2 results were positive on lean-body-mass endpoints, but the company planned to seek a partner or licensee before further clinical studies.
- Viking relies heavily on licensed technology from Ligand. The license includes potential development, regulatory, and sales milestones of up to approximately $1.54 billion in aggregate, plus tiered single-digit royalties; these are contingent obligations, not current debt.
- In December 2022, Viking filed trade-secret, contract, and related claims against Ascletis entities and an individual in federal court and brought a related action at the International Trade Commission. Viking said it intended to pursue its remedies; success is not assured.
- Principal risks include clinical-trial failure or delay, adverse safety findings, competition, dependence on third-party manufacturers and CROs, reliance on Ligand-licensed intellectual property, patent disputes, and the need for further financing. COVID-19-related trial and supplier disruption remained uncertain.
- The independent auditor gave an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal-control effectiveness because of the company’s filer status.
Investor facts to verify
- Whether VK2809’s VOYAGE primary-endpoint results were reported as expected, and how the longer-term histology results compare with the trial objectives.
- Subsequent cash use, financing, and updated runway assumptions against the stated first-quarter 2024 funding estimate.
- Progress, safety, enrollment, and next milestones for VK0214 and VK2735, and whether VK5211 has found a partner.
- Developments in the Ascletis litigation and any material implications for intellectual property or program execution.
- Remaining ATM capacity, repurchase activity, dilution, and potential Ligand milestone and royalty obligations as programs advance.